Cargando…
Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission
PURPOSE: To describe health-related quality of life (HRQoL) and dyspnea of COVID-19, 2 and 12 months after an intensive care unit (ICU) stay. METHODS: Patients discharged from the ICU between April and June 2020 and subsequently transferred to an inpatient rehabilitation facility were assessed 2 mon...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858438/ https://www.ncbi.nlm.nih.gov/pubmed/35184214 http://dx.doi.org/10.1186/s13613-022-00991-0 |
_version_ | 1784654241620557824 |
---|---|
author | Demoule, Alexandre Morawiec, Elise Decavele, Maxens Ohayon, Raphaelle Malrin, Roxane Galarza-Jimenez, Maria Alejandra Laveneziana, Pierantonio Morelot-Panzini, Capucine Similowski, Thomas De Rycke, Yann Gonzalez-Bermejo, Jesus |
author_facet | Demoule, Alexandre Morawiec, Elise Decavele, Maxens Ohayon, Raphaelle Malrin, Roxane Galarza-Jimenez, Maria Alejandra Laveneziana, Pierantonio Morelot-Panzini, Capucine Similowski, Thomas De Rycke, Yann Gonzalez-Bermejo, Jesus |
author_sort | Demoule, Alexandre |
collection | PubMed |
description | PURPOSE: To describe health-related quality of life (HRQoL) and dyspnea of COVID-19, 2 and 12 months after an intensive care unit (ICU) stay. METHODS: Patients discharged from the ICU between April and June 2020 and subsequently transferred to an inpatient rehabilitation facility were assessed 2 months and 12 months after ICU admission. HRQoL was assessed by the EuroQoL EQ-5D-3L (visual analog scale and time trade-off normalized to the French population algorithm) and dyspnea was assessed by the modified Medical Research Council (mMRC) dyspnea scale. RESULTS: We enrolled 94 patients. Median EQ-5D-3L time trade-off was 0.80 (interquartile range, 0.36–0.91) at 2 months and 0.91 (0.52–1.00) at 12 months (P = 0.12). EQ-5D-3L visual analog scale was 70 (60–85) at 2 months and 70 (60–85) at 12 months (P = 0.07). The mMRC dyspnea scale was 3 (2–4) at ICU discharge, 1 (0–2), P < 0.001 at 2 months and 1 (1–2) at 12 months. At 12 months, 68 (76%) patients reported at least one symptom that was not present prior to ICU admission and 27 (61%) of the 44 patients who were previously working had returned to work. On multiple linear regression, factors associated with EQ-5D-3L were body mass index on ICU admission, tracheostomy, male gender and active smoking. CONCLUSIONS: Twelve months after ICU admission for COVID-19 and subsequent rehabilitation, a substantial proportion of patients reported alterations of HRQoL, dyspnea and symptoms that were not present prior to admission and a substantial proportion of these patients had not returned to work. Factors associated with a risk of poorer 12-month quality of life, may help to identify at-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-022-00991-0. |
format | Online Article Text |
id | pubmed-8858438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88584382022-02-22 Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission Demoule, Alexandre Morawiec, Elise Decavele, Maxens Ohayon, Raphaelle Malrin, Roxane Galarza-Jimenez, Maria Alejandra Laveneziana, Pierantonio Morelot-Panzini, Capucine Similowski, Thomas De Rycke, Yann Gonzalez-Bermejo, Jesus Ann Intensive Care Research PURPOSE: To describe health-related quality of life (HRQoL) and dyspnea of COVID-19, 2 and 12 months after an intensive care unit (ICU) stay. METHODS: Patients discharged from the ICU between April and June 2020 and subsequently transferred to an inpatient rehabilitation facility were assessed 2 months and 12 months after ICU admission. HRQoL was assessed by the EuroQoL EQ-5D-3L (visual analog scale and time trade-off normalized to the French population algorithm) and dyspnea was assessed by the modified Medical Research Council (mMRC) dyspnea scale. RESULTS: We enrolled 94 patients. Median EQ-5D-3L time trade-off was 0.80 (interquartile range, 0.36–0.91) at 2 months and 0.91 (0.52–1.00) at 12 months (P = 0.12). EQ-5D-3L visual analog scale was 70 (60–85) at 2 months and 70 (60–85) at 12 months (P = 0.07). The mMRC dyspnea scale was 3 (2–4) at ICU discharge, 1 (0–2), P < 0.001 at 2 months and 1 (1–2) at 12 months. At 12 months, 68 (76%) patients reported at least one symptom that was not present prior to ICU admission and 27 (61%) of the 44 patients who were previously working had returned to work. On multiple linear regression, factors associated with EQ-5D-3L were body mass index on ICU admission, tracheostomy, male gender and active smoking. CONCLUSIONS: Twelve months after ICU admission for COVID-19 and subsequent rehabilitation, a substantial proportion of patients reported alterations of HRQoL, dyspnea and symptoms that were not present prior to admission and a substantial proportion of these patients had not returned to work. Factors associated with a risk of poorer 12-month quality of life, may help to identify at-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-022-00991-0. Springer International Publishing 2022-02-20 /pmc/articles/PMC8858438/ /pubmed/35184214 http://dx.doi.org/10.1186/s13613-022-00991-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Demoule, Alexandre Morawiec, Elise Decavele, Maxens Ohayon, Raphaelle Malrin, Roxane Galarza-Jimenez, Maria Alejandra Laveneziana, Pierantonio Morelot-Panzini, Capucine Similowski, Thomas De Rycke, Yann Gonzalez-Bermejo, Jesus Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title | Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title_full | Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title_fullStr | Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title_full_unstemmed | Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title_short | Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission |
title_sort | health-related quality of life of covid-19 two and 12 months after intensive care unit admission |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858438/ https://www.ncbi.nlm.nih.gov/pubmed/35184214 http://dx.doi.org/10.1186/s13613-022-00991-0 |
work_keys_str_mv | AT demoulealexandre healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT morawiecelise healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT decavelemaxens healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT ohayonraphaelle healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT malrinroxane healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT galarzajimenezmariaalejandra healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT lavenezianapierantonio healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT morelotpanzinicapucine healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT similowskithomas healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT deryckeyann healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission AT gonzalezbermejojesus healthrelatedqualityoflifeofcovid19twoand12monthsafterintensivecareunitadmission |